ImmunityBio, Inc. IBRX Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s operating lease liabilities?
- ImmunityBio, Inc. (IBRX) reported operating lease liabilities of $33.15M in Q1 2026.
- How has ImmunityBio, Inc.'s operating lease liabilities changed year-over-year?
- ImmunityBio, Inc.'s operating lease liabilities increased by 0.2% year-over-year, from $33.1M to $33.15M.
- What is the long-term trend for ImmunityBio, Inc.'s operating lease liabilities?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s operating lease liabilities has grown at a 15.6% compound annual growth rate (CAGR), from $16.18M to $33.45M.
- What does operating lease liabilities mean?
- The portion of lease payments due after more than one year.
- How do you interpret operating lease liabilities?
- An increase indicates a growing long-term commitment to leased assets, which may impact future cash flow flexibility.
- How does operating lease liabilities compare across companies?
- Standardized across companies reporting under modern lease accounting standards.